related documents
- Evaluating improvement in patient-reported dyspnea and pulmonary function tests (PFTs) in patients with malignant pleural mesothelioma (MPM): An analysis as part of the 448-patient randomized pemetrexed plus cisplatin versus cisplatin trial Conferences
- Long-term survival update from the randomized phase III study of pemetrexed plus cisplatin vs cisplatin in patients with malignant pleural mesothelioma (MPM) Conferences
- P-126 Activation of tyrosine kinase receptors and intracellular signal mediators in NSCLC tumors Conferences
- P-252 Interim report: A phase III randomized double blindchemoprevention trial of selenium supplementation in persons with resected stage I non small cell lung cancer Conferences
- P-936 Use of an algorithm to aid determination of causality in early clinical trials of lung cancer using targeted therapy Conferences
- Phase I/II study of GTI-2040 plus docetaxel as second-line treatment in advanced non-small cell lung cancer (NSCLC) Conferences
- Randomized Phase III Trial Comparing Irinotecan/Cisplatin With Etoposide/Cisplatin in Patients With Previously Untreated Extensive-Stage Disease Small-Cell Lung Cancer Conferences
- Reporting on consistency of clinical practice with lung cancer guidelines: A clinical monograph by Cancer Care Ontario Conferences
- Updated multiple regression analysis of prognostic variables for survival in malignant pleural mesothelioma (MPM): Observations from a phase III study of pemetrexed plus cisplatin versus cisplatin and evolution of the regression model Conferences
- Use of forced vital capacity (FVC) measurement for the clinical management of malignant pleural mesothelioma (MPM): Observations from the pemetrexed plus cisplatin versus cisplatin study Conferences